Cargando…

Targeted alpha therapy for glioblastoma

According to the 2021 World Health Organization Classification of Tumors of the Central Nervous System, glioblastoma (GB) is a primary brain tumor and presents with the worst prognosis. Due to its infiltrating characteristic, molecular heterogeneity, and only partly preserved function of the blood-b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kunikowska, Jolanta, Morgenstern, Alfred, Pełka, Kacper, Bruchertseifer, Frank, Królicki, Leszek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800503/ https://www.ncbi.nlm.nih.gov/pubmed/36590948 http://dx.doi.org/10.3389/fmed.2022.1085245

Ejemplares similares

Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy
por: Królicki, Leszek, et al.
Publicado: (2021)

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with (213)Bi-substance P analogue
por: Krolicki, Leszek, et al.
Publicado: (2018)

Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?
por: Krolicki, Leszek, et al.
Publicado: (2023)

Ga-68-PSMA-11 PET/CT in Patients with Biochemical Recurrence of Prostate Cancer after Primary Treatment with Curative Intent—Impact of Delayed Imaging
por: Kunikowska, Jolanta, et al.
Publicado: (2022)

An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018)

Expression of glutamate carboxypeptidase II in the glial tumor recurrence evaluated in vivo using radionuclide imaging
por: Kunikowska, Jolanta, et al.
Publicado: (2022)

Nuclear imaging and therapy in oncology in Poland in 2021–2022
por: Kunikowska, Jolanta, et al.
Publicado: (2023)

Tumor uptake in glioblastoma multiforme after IV injection of [(177)Lu]Lu-PSMA-617
por: Kunikowska, Jolanta, et al.
Publicado: (2020)

Functionalized NaA nanozeolites labeled with (224,225)Ra for targeted alpha therapy
por: Piotrowska, Agata, et al.
Publicado: (2013)

Alpha Particles Induce Autophagy in Multiple Myeloma Cells
por: Gorin, Jean-Baptiste, et al.
Publicado: (2015)

[(68) Ga]Ga-PSMA-11 in diagnosis and follow-up after transarterial chemoembolization in hepatocellular carcinoma
por: Kunikowska, Jolanta, et al.
Publicado: (2023)

Global experience with PSMA-based alpha therapy in prostate cancer
por: Sathekge, Mike M., et al.
Publicado: (2021)

Functionalized TiO(2) nanoparticles labelled with (225)Ac for targeted alpha radionuclide therapy
por: Cędrowska, Edyta, et al.
Publicado: (2018)

Clinical results of radionuclide therapy of neuroendocrine tumours with (90)Y-DOTATATE and tandem (90)Y/(177)Lu-DOTATATE: which is a better therapy option?
por: Kunikowska, Jolanta, et al.
Publicado: (2011)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis
por: Derrien, Aurélie, et al.
Publicado: (2015)

What parameters from (18)F-FDG PET/CT are useful in evaluation of adrenal lesions?
por: Kunikowska, Jolanta, et al.
Publicado: (2014)

[(68) Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma
por: Kunikowska, Jolanta, et al.
Publicado: (2020)

Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate
por: Chan, Ho Sze, et al.
Publicado: (2016)

Optimizing labelling conditions of (213)Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
por: Chan, Ho Sze, et al.
Publicado: (2016)

Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model
por: Capitao, Marisa, et al.
Publicado: (2021)

Development of [(225)Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
por: Hooijman, Eline L., et al.
Publicado: (2021)

Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics
por: Šimeček, Jakub, et al.
Publicado: (2018)

Alpha-Particle Emitting (213)Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation
por: Wulbrand, Christian, et al.
Publicado: (2013)

Supply and Clinical Application of Actinium-225 and Bismuth-213
por: Morgenstern, Alfred, et al.
Publicado: (2020)

Revisiting the Radiobiology of Targeted Alpha Therapy
por: Pouget, Jean-Pierre, et al.
Publicado: (2021)

Tandem peptide receptor radionuclide therapy using (90)Y/(177)Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience
por: Kunikowska, Jolanta, et al.
Publicado: (2020)

The Safety and Efficacy of the Repeated PRRT with [(90)Y]Y/[(177)Lu]Lu-DOTATATE in Patients with NET
por: Zemczak, Anna, et al.
Publicado: (2021)

Editorial: Targeted alpha particle therapy in oncology
por: Bruland, Øyvind Sverre, et al.
Publicado: (2023)

Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model
por: Fichou, Nolwenn, et al.
Publicado: (2015)

Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
por: Gawęda, Weronika, et al.
Publicado: (2020)

Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected Individuals
por: Tsukrov, Dina, et al.
Publicado: (2016)

First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
por: Handula, Maryana, et al.
Publicado: (2023)

DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy
por: Graf, Franziska, et al.
Publicado: (2014)

Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer
por: Yoshida, Takahiro, et al.
Publicado: (2016)

(213)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
por: Kratochwil, C., et al.
Publicado: (2014)

Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model
por: Nedrow, Jessie R., et al.
Publicado: (2017)

Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?
por: Pallares, Roger M., et al.
Publicado: (2022)

Radium and Francium beam tests to produce 225Ac/ 213Bi generators at CERN-MEDICIS
por: Bruchertseifer, Frank, et al.
Publicado: (2015)

Multimodality imaging in a diagnostic and therapeutic process of a patient with infective endocarditis
por: Binkiewicz-Orluk, Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_329fuk81eklq0t16jf2s2gogrk